Matthew Brown

Matthew Brown


Dr. Todd Brusko, PhD


College of Medicine


Biochemistry & Molecular Biology




UF Diabetes Institute, American Diabetes Association

Academic Awards

ESP 2020, USP 2020


UFHealth Shands Hospital

Research Interests

Type 1 Diabetes, Autoimmunity, Immunotherapy

Hobbies and Interests

Tennis, reading, and hiking

Research Project

Evaluating the Therapeutic Potential of Modulating the CD226/TIGIT Costimulatory Pathway for the Treatment of Type 1 Diabetes

Type 1 Diabetes (T1D) is an autoimmune disease characterized by the body’s immune cells, including T cells and potentially natural killer (NK) cells, attacking the insulin-producing pancreatic β-cells. This investigation seeks to examine how two costimulatory proteins, CD226 and TIGIT, responsible for the immunoregulation of immune cells, can be modulated to develop new therapeutic approaches to treat T1D. To evaluate this costimulatory pathway in the context of translational medicine applications, I will be examining the therapeutic potential of isolating CD226 deficient Human Regulatory T cells (Tregs) for use in adoptive cell therapies, as well as the potential of CD226 monoclonal antibody therapies using the NOD mouse model.